Special Session

Presidential Symposium II - EL09 - RT is Becoming the Standard for Curing Oligometastatic Lung Cancer

9/15/2019
10:15 AM - 11:45 AM
Location: Room W186

Session Type: Special Session
0.00 AMA PRA Category 1 Credits™

We will review the evolving role of radiotherapy (RT) in the management of metastatic non-small cell lung carcinoma (NSCLC). Speakers Percy Lee and Kristin Higgins will summarize standard-of-care (SOC) therapies and emerging RT data in this disease. For most patients, immune checkpoint inhibitors (ICI) with/without chemotherapy is the SOC (1-5), while tyrosine kinase inhibitors (TKI) treat oncogene-driven tumors (EGFR, etc) (6-10). Historically, radical local therapy has been employed to cure NSCLC patients with typically solitary brain or adrenal metastases (11-13). With recent advances in systemic therapies, there exists opportunities to expand the use of RT to NSCLC patients with limited metastases in order to extend lives (14-16). Questions we hope to address include predictive biomarkers to guide the use of upfront or consolidation RT, innovative technologies to minimize toxicity, and research necessary to support the standard use of RT in patients with oligometastatic NSCLC. RT for "cure" of oligometastatic NSCLC is open for debate.

During this session attendees will listen to two level setting talks. From there attendees will being small group discussion on their assigned topic and side, Pro or Con. They will formulate opening statements, points for arguments and closing statements. Volunteer audience members will then take place in moderated mini debates. The session will end with a vote on the best debate argument and a wrap up with a take home message.

Presentations:

Henning Willers, MD

Massachusetts General Hospital

Biography:
Henning Willers, MD, is a clinician-scientist in the Department of Radiation Oncology at Massachusetts General Hospital (MGH) and an Associate Professor at Harvard Medical School.
Dr. Willers obtained his MD degree at the University of Hamburg, Germany, in 1994. Following a postdoctoral fellowship under Simon N. Powell, MD, PhD, and radiation oncology residency training at MGH, he joined the MGH faculty in 2005. In 2008, Dr. Willers established the Pulmonary SBRT Program at the MGH, and in 2016, he was named the Director of the Thoracic Radiation Oncology Program at MGH, succeeding Noah C. Choi, MD.
NCI-funded research in his laboratory focuses on molecular mechanisms of radiation resistance and the identification of targeted radiosensitizers and associated biomarkers. Another major interest is the targeting of DNA repair pathways in lung and other cancers with proton radiation and PARP inhibitors.
Dr. Willers has also led or co-led clinical trials on esophagus sparing with IMRT in locally advanced lung cancer, the integration of chemoradiation with EGFR inhibition in EGFR mutant non-metastatic lung cancer, the use of consolidation radiation therapy in metastatic oncogene-driven lung cancer, and the combination of PARP and EGFR inhibitors in metastatic EGFR mutant lung cancer.
Other current activities include service on the Governing Council of the Radiation Research Society, on the Editorial Board of Radiotherapy & Oncology, and on the ABR Radiation Biology Committee.
Follow him on Twitter: @henningwillers

Presentation(s):

Send Email for Henning Willers

Khinh Ranh Voong, MD, MPH

Johns Hopkins Radiation Oncology Kimmel Cancer Center

Biography:
K. Ranh Voong, MD, is an Assistant Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University. Dr. Voong specializes in the treatment of thoracic tumors at the Johns Hopkins Thoracic Center of Excellence at Bayview.
Dr. Voong graduated summa cum laude from the University of Pennsylvania and with Alpha Omega Alpha honors from Johns Hopkins University School of Medicine. She completed internship training in the Johns Hopkins Hospital Olser Medical Housestaff Program, residency training in Radiation Oncology at the University of Texas MD Anderson Cancer Center, and a Master’s in Public Health in with a focus on biostatistics and health economic evaluation at the University of Texas Health Science Center in Houston. Dr. Voong has been recognized for her skill as a physician and was recognized by the MD Anderson faculty for her exceptional patient care with the Dr. Mary Fletcher Award for Excellence in Clinical Care. She has been recognized for her dedication to teaching by the residents of the Johns Hopkins Department of Radiation Oncology with the Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award.

She has been awarded by the Lung Cancer Research Foundation for her research on the immune effects induced by stereotactic ablative radiation therapy in non-small cell lung cancer. Dr. Voong leads a pilot study at John Hopkins University that examines the immune effects in the treatment of lung cancer with radiation alone. Her research interests also include improving patient care through reducing toxicity using patient reported outcomes and health-economic evaluation. She is the quality of life co-chair in LU006, a NRG Oncology/Alliance study evaluating the potential benefit of the addition of pleural radiation in patients with mesothelioma. She was also awarded Radiation Oncology Institute’s 2017 Value of Radiation Publication Award.

Presentation(s):

Send Email for Khinh Ranh Voong


Assets

Presidential Symposium II - EL09 - RT is Becoming the Standard for Curing Oligometastatic Lung Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL09 - RT is Becoming the Standard for Curing Oligometastatic Lung Cancer